Abraxis, Otsuka Holdings preclinical data

In a mouse model of inflammatory breast cancer, Abraxane plus Avastin bevacizumab inhibited tumor growth by 96% vs. 73% for Abraxane alone. Combination therapy also led to a complete response rate of 22%. Data were presented at the American Association for Cancer Research meeting in Washington. ...